[doptabs]
[doptab title=”Overview”]

Alabama Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Alabama

Alabama Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Alabama Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Alabama Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

[/doptab]
[doptab title=”Treatment and Research”]

Research

[dopaccordions]
[dopaccordion title=”Robert, Francisco Onconase Vs Doxorubicin In Malignant Mesothelioma
Grant: 5M01RR000032-390649″ icon=27 activeicon=28]

Abstract: Doxorubicin is a commonly used chemotherapy agent in the treatment of malignant mesothelioma. Onconase is an experimental (not approved by the FDA) drug that has shown activity against malignant mesothelioma. The purpose of this study is to determine whether Onconase, when administered into the blood stream, is better than injection of Doxorubicin into the blood stream for the treatment of malignant mesothelioma. Approximately 160 patients across the country will be enrolled on this study. These patients will receive either Onconase by intravenous infusion over 30 minutes weekly, or Doxorubicin every 3 weeks for a maximum of 6 doses. Treatment will continue for at least 18 weeks or until the tumor is no longer responding to treatment. After treatment has been stopped, patients will be monitored by a physician to determine late side effects and future therapy. 

Tags: Antineoplastic, Doxorubicin, Human Therapy Evaluation, Mesothelioma, Neoplasm /cancer Chemotherapy Clinical Trial Clinical Research, Human Subject

  • Followup Grant: 5M01RR000032-400649
  • Followup Grant: 5M01RR000032-410649
  • Followup Grant: 5M01RR000032-420649

[/dopaccordion]
[/dopaccordions]

Clinical Trials

[dopaccordions]
[dopaccordion title=”Active, not recruiting PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma

Intervention: Drug: vatalanib

More Information

[/dopaccordion]
[dopaccordion title=”Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Alanosine in Treating Patients With Cancer” icon=27 activeicon=28]

Condition: Lung Cancer;   Malignant Mesothelioma;   Pancreatic Cancer;   Sarcoma
Intervention: Drug: L-alanosine
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gefitinib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Capecitabine in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

[/dopaccordion]
[/dopaccordions]
[/doptab]
[doptab title=”Doctors and Hospital”]

Hospitals and Cancer Centers

University of Alabama at Birmingham Comprehensive Cancer Center

1824 6th Ave. S. 236 TI
Birmingham, AL
205-975-8222 

Physicians

Dr. Robert J. Cerfolio

Thoracic Surgeon
University of Alabama at Birmingham
Department of Cardiothoracic Surgery
703 19th Street
Birmingham, Alabama 35294
(205)934-5937

[/doptab]
[doptab title=”Cases”]

Henderson v. Meadwestvaco Corp.
1070522, 1070497, 1070509, SUPREME COURT OF ALABAMA, March 20, 2009, Released

GMC v. Kilgore
1002149 , SUPREME COURT OF ALABAMA, December 20, 2002, Released

Southern Bakeries, Inc. v. Knipp
1010743 , SUPREME COURT OF ALABAMA, December 13, 2002, Released

Greene v. Csx Transp.
1010357 , SUPREME COURT OF ALABAMA, August 30, 2002, Released

Ex parte Wilkerson
1990769, SUPREME COURT OF ALABAMA, September 8, 2000, Released

Wilkerson v. Burlington N. R.R.
2980962, COURT OF CIVIL APPEALS OF ALABAMA, September 24, 1999, Released

[/doptab]
[doptab title=”Lawyers”]

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.

[/doptab]
[/doptabs]